MiNK Therapeutics, Inc. (INKT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

1.7100

+0.0300

(+1.79%)

At close: 04:00PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Price Crosses Moving Average

View all chart patterns

Performance Outlook

Previous Close	1.6800
Open	1.6300
Bid	1.5500 x 1100
Ask	1.7400 x 1100
Day's Range	1.6000 - 1.8300
52 Week Range	1.0900 - 22.1550
Volume	106,620
Avg. Volume	96,919

Market Cap	57.389M
Beta (5Y Monthly)	N/A
PE Ratio (TTM)	N/A
EPS (TTM)	-1.2040
Earnings Date	Aug 09, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	9.33

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for INKT

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

MiNK Therapeutics, Inc.
Daily – Vickers Top Buyers & Sellers for 07/22/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Rating
Fair Value
Economic Moat
23 days agoArgus Research

All

GlobeNewswire
MiNK Therapeutics Reports Corporate Update and Second Quarter 2022 Financial Results
Novel stromal-CAR-iNKT shows activity in solid tumors; FIH planned for 2023Clinical presentation of AgenT-797 in solid tumors, myeloma, and ARDS planned for 2H2022Under the leadership team of Dr. Joy Zhou, completed internal cGMP production of AgenT-797 with expansion capacity to treat >700,000 patients/yearAgenT-797 for the treatment of infections and viral ARDS identified as selectable for funding by DARPA; contract negotiations underway NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- MiNK Therape
- PLx Pharma Inc. Reports Second Quarter 2022 Results and Provides Business Update
  GlobeNewswire
- United-Guardian Reports Second Quarter Financial Results
  GlobeNewswire
GlobeNewswire
MiNK Therapeutics to Participate at BTIG Biotechnology Conference
NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that the Company will attend the BTIG 2022 Biotechnology Conference. MiNK will participate virtually and host one-on-one meetings with investors on August 8th and 9th. About MiNK Therape
GlobeNewswire
MiNK Therapeutics to Report Second Quarter 2022 Financial Results and Business Update
Conference Call on Tuesday, August 9th 2022, at 11:00 a.m. ETNEW YORK, July 27, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced it will release its second quarter 2022 financial results before the market opens on Tuesday, August 9th, 2022. MiNK leadersh